EMERGING ANTI-INFLAMMATORY POTENTIALS OF SOME NOVEL SCHIFF’S BASE DERIVATIVES OF 3, 4- DIOXYMETHYLENE ACETOPHENONE

Abstract

Inflammation represents a physical challenge to the human by offering acute pain, edema, redness, and bodily discomfort. The
area of drug discovery is a continuous process for designing and fabricating better non-steroidal anti-inflammation drugs (NSAIDs). However,
they suffer from abundant side-effects such as bleeding in GIT, stomach pain, heartburn, etc. Objective: Based on the path of new drug
discovery, the present investigation aimed at exploration of anti-inflammatory potential of two Schiff’s base containing 3, 4-dioxymethylene
based compounds. Materials and Methods: (Z)-4-(2-aminoethyl)-N-(1-(benzo[d][1,3]dioxol-5-yl)ethylidene)aniline (3) (at 100 mg/kg b.w.) and
(Z)-N-(1-(benzo[d][1,3]dioxol-5-yl)ethylidene)-4-(2-(methylamino)ethyl)aniline (5) (at 100 mg/kg b.w.) were screened for edema reducing
potentials using carrageenan-induced paw edema method with comparison to the standard drug indomethacin (at 10 mg/kg b.w.). Results and
Discussion: The molecule (3) exhibited % edema reduction of 14.88%, 27.64%, and 38.24%, respectively at 1 hr, 2 hr, and 3 hr. The compound
(5) demonstrated % edema reduction of 20.53%, 31.49%, and 44.13%, respectively at first hr, second hr, and third hr. The synthesized Schiff’s
base molecules expressed noteworthy activity as compared to indomethacin (standard drug). Conclusion: The present research represented the
importance of Schiff’s base containing 3,4-dioxymethylene hybrid compounds and will open new avenues in pharmacotherapeutics. The study
will also motivate the researchers across the globe in developing still better molecules with better therapeutic index.